Which company develops and produces Mobocertinib?

Mobocertinib, also known as TAK-788, is a drug developed and produced by the Japanese pharmaceutical company Takeda (Takeda Pharmaceutical Company Limited). Takeda Pharmaceuticals is a global pharmaceutical company headquartered in Japan that focuses on the development and production of drugs for the treatment of a variety of diseases.

Mobosetinib is a tyrosine kinase inhibitor developed to target a specific type of molecular driver in non-small cell lung cancer (NSCLC), namely EGFR (epidermal growth factor receptor) mutations. This mutation drives tumor growth in a subset of patients with NSCLC, so the drug is being developed to provide an effective treatment option, especially for those who are resistant to other treatment options.

Mobosetinib has shown potential in clinical trials and has been approved in several countries for the treatment of EGFR mutation-positive NSCLC patients. This achievement represents Takada's important contribution in the field of lung cancer treatment.

In short, moboxetinib is a drug developed and produced by Takeda Pharmaceuticals of Japan. It represents the company's innovation and efforts in the field of cancer treatment and provides patients with a new treatment option to help them deal with the serious disease of non-small cell lung cancer. The development and approval of this drug marks the pharmaceutical industry's ongoing efforts to find more effective treatments.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.